ID

31770

Descripción

Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ); ODM derived from: https://clinicaltrials.gov/show/NCT00773838

Link

https://clinicaltrials.gov/show/NCT00773838

Palabras clave

Versiones (1)
  1. 27/9/18 27/9/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

27 de septiembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Relapsed or Refractory Multiple Myeloma NCT00773838

Inglés

Eligibility Relapsed or Refractory Multiple Myeloma NCT00773838

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patient is 18 years of age or older
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
patient has an established diagnosis of multiple myeloma based on myeloma diagnostic criteria
Descripción

Multiple Myeloma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0026764
patient must have adequate organ function
Descripción

Organ function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0678852
patient is refractory to prior bortezomib regimen and have also been exposed to prior imid (thalidimide or lenalidmide)
Descripción

Bortezomib refractory | Exposure to Imide | Exposure to Thalidomide | Exposure to Lenalidomide

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1176309
UMLS CUI [1,2]
C0205269
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C0020926
UMLS CUI [3,1]
C0332157
UMLS CUI [3,2]
C0039736
UMLS CUI [4,1]
C0332157
UMLS CUI [4,2]
C1144149
patient has relapsed and refractory multiple myeloma after at lest 2 prior treatment regimens
Descripción

Relapse multiple myeloma | Refractory multiple myeloma | Status post Therapeutic procedure Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2349261
UMLS CUI [2]
C0278620
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C0087111
UMLS CUI [3,3]
C1265611
patient is relapsed, refractory, intolerant, and/or ineligible (in the opinion of the investigator) to other therapies including an imid (thalidomide or lenalidomide)
Descripción

Other Therapy Relapse | Other Therapy refractory | Intolerant Other Therapy | Ineligibility Other Therapy | Imide | Thalidomide | lenalidomide

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0205394
UMLS CUI [1,3]
C0277556
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0205394
UMLS CUI [2,3]
C0205269
UMLS CUI [3,1]
C0231200
UMLS CUI [3,2]
C0087111
UMLS CUI [3,3]
C0205394
UMLS CUI [4,1]
C1512714
UMLS CUI [4,2]
C0087111
UMLS CUI [4,3]
C0205394
UMLS CUI [5]
C0020926
UMLS CUI [6]
C0039736
UMLS CUI [7]
C1144149
patient is refractory to bortezomib (no response on prior bortezomib containing regimen or progression on or within 60 days of bortezomib containing regimen
Descripción

Bortezomib refractory | Therapeutic procedure Containing Bortezomib | Disease Progression

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1176309
UMLS CUI [1,2]
C0205269
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0332256
UMLS CUI [2,3]
C1176309
UMLS CUI [3]
C0242656
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient has known hypersensitivity to any components of bortezomib or vorinostat
Descripción

Hypersensitivity Bortezomib Component | Hypersensitivity Vorinostat Component

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1176309
UMLS CUI [1,3]
C1705248
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0672708
UMLS CUI [2,3]
C1705248
patient has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation within 4 weeks of the initiation of study therapy
Descripción

Allogeneic bone marrow transplantation | Bone Marrow Transplantation Planned

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0149615
UMLS CUI [2,1]
C0005961
UMLS CUI [2,2]
C1301732
patient has known hypersensitivity to any components of bortezomib or vorinostat
Descripción

Hypersensitivity Bortezomib Component | Hypersensitivity Vorinostat Component

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1176309
UMLS CUI [1,3]
C1705248
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0672708
UMLS CUI [2,3]
C1705248
patient has active hepatitis b or c, plasma cell leukemia, or is hiv positive
Descripción

Hepatitis B | Hepatitis C | Leukemia, Plasma Cell | HIV Seropositivity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019163
UMLS CUI [2]
C0019196
UMLS CUI [3]
C0023484
UMLS CUI [4]
C0019699
Volver a la parte superior de la página

Similar models

Eligibility Relapsed or Refractory Multiple Myeloma NCT00773838

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
patient is 18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Multiple Myeloma
Item
patient has an established diagnosis of multiple myeloma based on myeloma diagnostic criteria
boolean
C0026764 (UMLS CUI [1])
Organ function
Item
patient must have adequate organ function
boolean
C0678852 (UMLS CUI [1])
Bortezomib refractory | Exposure to Imide | Exposure to Thalidomide | Exposure to Lenalidomide
Item
patient is refractory to prior bortezomib regimen and have also been exposed to prior imid (thalidimide or lenalidmide)
boolean
C1176309 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C0020926 (UMLS CUI [2,2])
C0332157 (UMLS CUI [3,1])
C0039736 (UMLS CUI [3,2])
C0332157 (UMLS CUI [4,1])
C1144149 (UMLS CUI [4,2])
Relapse multiple myeloma | Refractory multiple myeloma | Status post Therapeutic procedure Quantity
Item
patient has relapsed and refractory multiple myeloma after at lest 2 prior treatment regimens
boolean
C2349261 (UMLS CUI [1])
C0278620 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Other Therapy Relapse | Other Therapy refractory | Intolerant Other Therapy | Ineligibility Other Therapy | Imide | Thalidomide | lenalidomide
Item
patient is relapsed, refractory, intolerant, and/or ineligible (in the opinion of the investigator) to other therapies including an imid (thalidomide or lenalidomide)
boolean
C0087111 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0277556 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C0205394 (UMLS CUI [2,2])
C0205269 (UMLS CUI [2,3])
C0231200 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C0205394 (UMLS CUI [3,3])
C1512714 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C0205394 (UMLS CUI [4,3])
C0020926 (UMLS CUI [5])
C0039736 (UMLS CUI [6])
C1144149 (UMLS CUI [7])
Bortezomib refractory | Therapeutic procedure Containing Bortezomib | Disease Progression
Item
patient is refractory to bortezomib (no response on prior bortezomib containing regimen or progression on or within 60 days of bortezomib containing regimen
boolean
C1176309 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0332256 (UMLS CUI [2,2])
C1176309 (UMLS CUI [2,3])
C0242656 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Bortezomib Component | Hypersensitivity Vorinostat Component
Item
patient has known hypersensitivity to any components of bortezomib or vorinostat
boolean
C0020517 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0672708 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
Allogeneic bone marrow transplantation | Bone Marrow Transplantation Planned
Item
patient has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation within 4 weeks of the initiation of study therapy
boolean
C0149615 (UMLS CUI [1])
C0005961 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
Hypersensitivity Bortezomib Component | Hypersensitivity Vorinostat Component
Item
patient has known hypersensitivity to any components of bortezomib or vorinostat
boolean
C0020517 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0672708 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
Hepatitis B | Hepatitis C | Leukemia, Plasma Cell | HIV Seropositivity
Item
patient has active hepatitis b or c, plasma cell leukemia, or is hiv positive
boolean
C0019163 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
C0023484 (UMLS CUI [3])
C0019699 (UMLS CUI [4])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial